United Therapeutics (UTHR) Equity Average (2016 - 2025)
Historic Equity Average for United Therapeutics (UTHR) over the last 16 years, with Q3 2025 value amounting to $6.9 billion.
- United Therapeutics' Equity Average rose 1666.12% to $6.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 billion, marking a year-over-year increase of 1666.12%. This contributed to the annual value of $6.2 billion for FY2024, which is 1527.9% up from last year.
- United Therapeutics' Equity Average amounted to $6.9 billion in Q3 2025, which was up 1666.12% from $7.0 billion recorded in Q2 2025.
- In the past 5 years, United Therapeutics' Equity Average registered a high of $7.0 billion during Q2 2025, and its lowest value of $3.4 billion during Q1 2021.
- Its 5-year average for Equity Average is $5.1 billion, with a median of $5.3 billion in 2023.
- Per our database at Business Quant, United Therapeutics' Equity Average surged by 475.69% in 2024 and then surged by 2669.16% in 2025.
- United Therapeutics' Equity Average (Quarter) stood at $3.9 billion in 2021, then increased by 20.16% to $4.7 billion in 2022, then grew by 24.98% to $5.8 billion in 2023, then increased by 7.25% to $6.3 billion in 2024, then rose by 9.72% to $6.9 billion in 2025.
- Its Equity Average was $6.9 billion in Q3 2025, compared to $7.0 billion in Q2 2025 and $6.6 billion in Q1 2025.